Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
Open Access
- 10 March 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 7 (3), e540
- https://doi.org/10.1038/bcj.2017.18
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 studyInternational Journal of Hematology, 2016
- Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)Clinical Lymphoma Myeloma and Leukemia, 2015
- Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2015
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple MyelomaClinical Cancer Research, 2008